Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) just unveiled an update.
Jacobio Pharmaceuticals Group Co., Ltd. has announced a capital increase and equity transfer agreement involving its subsidiaries and partners, including Oceanpine Capital. This strategic move allows Jacobio to focus on its core oncology therapies while optimizing capital allocation and enhancing organizational efficiency. The proceeds from the transaction will be used to advance the company’s Pan-KRAS inhibitor and other innovative oncology projects, aligning with its strategic goals and benefiting shareholders.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. operates in the pharmaceutical industry, focusing on the development and provision of innovative oncology therapies. The company is committed to improving health through its key pipeline products targeting various cellular pathways, including KRAS, MYC, P53, and tumor immunity.
Average Trading Volume: 9,736,748
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.23B
For an in-depth examination of 1167 stock, go to TipRanks’ Overview page.